# Immune & Thymic Peptide FAQ — Thymosin Alpha-1, Thymulin, KPV — Lazarus Research Peptides > Frequently asked questions about three Immune & Thymic research peptides — Thymosin Alpha-1, Thymulin, and KPV — answered from the peer-reviewed literature, with citations. Direct, citation-anchored answers to the questions readers most often bring to these three immune and thymic peptides. ## What is Thymosin Alpha-1? Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide. It was first isolated from calf thymus fraction 5 in 1977 by Goldstein and colleagues, who determined its complete sequence [7]. In the body it is derived from a larger precursor called prothymosin alpha; the synthetic version, thymalfasin, is sequence-identical and is approved as a drug in more than 35 countries [2]. It is distinct from Thymulin (a zinc-dependent 9-amino-acid hormone) and from thymosin beta-4 / TB-500 (an actin-binding peptide from a completely different protein family). ## What does Thymosin Alpha-1 do? At the mechanistic level, Thymosin Alpha-1 operates at the innate-adaptive immune interface. It signals through Toll-like receptors — particularly TLR2 and TLR9 — on dendritic cells and monocytes, promoting their maturation and interleukin-12 production, which in turn drives T-cell differentiation toward a Th1 (effector) profile. In parallel, it activates the IDO/tryptophan-catabolism pathway to generate regulatory T cells and interleukin-10, providing a counterbalancing tolerogenic signal [6]. In practice — in animals and in clinical settings — this dual profile has been studied for restoring immune function in states of depletion: chronic viral hepatitis, sepsis-related immunosuppression, and cancer-related T-cell exhaustion [3][4]. ## What is Thymosin Alpha-1 used for in research? The research and clinical-use base spans several areas. In chronic viral hepatitis (both B and C), thymalfasin is an approved treatment in multiple countries based on its immune-stimulatory properties [2]. In sepsis, it has been studied in two large controlled trials — ETASS (marginal positive signal at conventional significance) [5] and TESTS (null result in 1,106 patients) [1]. In oncology, it is explored as an immunostimulatory adjuvant alongside chemotherapy and checkpoint inhibitors in melanoma, hepatocellular carcinoma, and lung cancer [4]. A retrospective COVID-19 cohort found it associated with reversal of T-cell exhaustion and lower mortality in severe cases [3]. ## Is Thymosin Alpha-1 FDA-approved? No. Thymosin Alpha-1 (thymalfasin) is **not** FDA-approved for marketing in the United States. It is approved as a drug in more than 35 other countries for indications including chronic hepatitis B and C and adjunctive immunomodulation in cancer [2]. In the US, use is limited to investigational settings and compounding; it is not available as a marketed pharmaceutical. Research-grade material sold as a research chemical falls outside the regulated drug-quality chain [2]. ## What is Thymulin? Thymulin is a nine-amino-acid thymic hormone (sequence: pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) produced exclusively by thymic epithelial cells. It was historically called serum thymic factor (FTS). Its defining property is absolute zinc-dependence: the peptide is biologically inert without zinc and becomes active only when bound to one zinc(II) ion in a 1:1 ratio [12]. It drives T-lymphocyte differentiation and participates in a bidirectional thymus-neuroendocrine axis, signaling between the thymus and the pituitary [11]. ## What is Thymulin peptide used for in research? Thymulin research has followed two main tracks. First, classic immunology: understanding how thymic epithelial cells regulate T-lymphocyte maturation through the zinc-thymulin hormone signal, and how zinc deficiency depresses immune function by lowering thymulin activity [12]. Second, gene therapy: because thymulin production declines with age and thymic involution, researchers have used thymulin-expressing adenoviral and nanoparticle vectors to restore circulating thymulin in athymic animal models [9] and to deliver anti-inflammatory thymulin locally in the lung to reverse established asthma pathology [8]. ## Is Thymulin the same as serum thymic factor (FTS)? Yes. Thymulin and serum thymic factor (FTS, from *facteur thymique serique*) are the same molecule. The FTS designation was used in earlier literature; "thymulin" is the current preferred name. The active form is always the zinc-bound complex (Zn-thymulin or FTS-Zn). The zinc-free apopeptide is biologically inactive and is not detected by the bioassays that measure "thymulin activity" in serum [12]. ## How is Thymulin different from Thymosin Alpha-1? They are chemically and mechanistically distinct. Thymulin is a 9-amino-acid zinc-dependent hormone produced only by thymic epithelial cells; it acts as the thymus's own output signal, directly regulating T-cell maturation and communicating with the neuroendocrine system [12][11]. Thymosin Alpha-1 is a 28-amino-acid N-terminally acetylated peptide that acts at the innate-adaptive immune interface, signaling through Toll-like receptors on dendritic cells to orchestrate T-cell polarization and tolerogenic regulation [6]. Different sizes, different sequences, different receptors, different mechanisms. Neither derives from the other. ## What is KPV peptide? KPV is a three-amino-acid peptide — lysine (K), proline (P), valine (V) — corresponding to residues 11-13 of the hormone alpha-MSH. It is also written as alpha-MSH(11-13). Its defining feature is that it retains the parent hormone's anti-inflammatory activity while discarding its melanogenic (pigment-producing) effect [17]. It is a research peptide with no approved drug or dietary-supplement status and no validated human pharmacokinetics. ## What does KPV peptide do? KPV suppresses inflammation primarily by inhibiting NF-kB and MAP-kinase signaling pathways inside cells, reducing pro-inflammatory cytokines including IL-1beta and TNF-alpha [15]. In intestinal epithelial cells it is taken up directly via the PepT1 di/tripeptide transporter, which is upregulated in inflamed tissue — creating a built-in selectivity for active inflammation sites [15]. Its anti-inflammatory effect operates independently of the MC1R melanocortin receptor [16]. Most of its research is in mouse models of gut inflammation. ## What is KPV peptide good for, according to the research? The research signal is strongest for quieting gut inflammation. In mouse DSS-colitis and adoptive-transfer colitis models, KPV reduced inflammatory infiltrate, myeloperoxidase activity, and colonic damage while accelerating recovery [16]. Targeted delivery systems — both hyaluronic-acid nanoparticles [14] and PepT1-targeted nanodrugs [13] — outperformed non-targeted formulations in delivering KPV to inflamed colon tissue. A comprehensive review also documents anti-inflammatory activity across a broader range of models, including skin, eye, airway, and joints [17]. All of this is preclinical; KPV is not an approved treatment for any condition, and this site gives no dosing or medical advice [15]. ## Are Thymosin Alpha-1, Thymulin, and KPV the same thing as thymosin beta-4 or TB-500? No. They are completely different molecules from different protein families. Thymosin beta-4 (and its synthetic fragment TB-500) is an actin-binding peptide that promotes cell migration and wound healing; it derives from the beta-thymosin protein family. Thymosin Alpha-1 derives from prothymosin alpha and acts as an immunomodulatory signal through TLR-mediated dendritic-cell activation. Thymulin is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells. KPV is a melanocortin-derived anti-inflammatory tripeptide. The word "thymosin" appears in two of the names by historical convention, but it does not imply chemical or mechanistic similarity. These are distinct molecules with distinct mechanisms. --- A literature digest of peer-reviewed immune and thymic peptide research — citations in hand, no products on offer.